Squarepoint Ops LLC Has $2.06 Million Stake in Repligen Co. (NASDAQ:RGEN)

Squarepoint Ops LLC decreased its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 85.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,291 shares of the biotechnology company's stock after selling 81,814 shares during the period. Squarepoint Ops LLC's holdings in Repligen were worth $2,057,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in RGEN. Price T Rowe Associates Inc. MD increased its position in Repligen by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after acquiring an additional 743,815 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Repligen by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock valued at $734,251,000 after purchasing an additional 56,723 shares during the last quarter. Champlain Investment Partners LLC increased its holdings in shares of Repligen by 8.6% in the fourth quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock valued at $222,176,000 after purchasing an additional 122,595 shares in the last quarter. Alliancebernstein L.P. raised its position in Repligen by 23.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock worth $145,508,000 after purchasing an additional 191,439 shares during the last quarter. Finally, Conestoga Capital Advisors LLC lifted its holdings in Repligen by 0.7% during the 4th quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock worth $136,395,000 after buying an additional 6,872 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Insider Transactions at Repligen

In related news, Director Margaret Pax purchased 250 shares of Repligen stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. This represents a 31.53% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.20% of the stock is currently owned by insiders.

Repligen Trading Up 0.4%

RGEN traded up $0.50 during mid-day trading on Monday, hitting $118.57. The stock had a trading volume of 1,132,153 shares, compared to its average volume of 744,736. The stock's fifty day simple moving average is $127.67 and its 200-day simple moving average is $143.61. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a market capitalization of $6.66 billion, a price-to-earnings ratio of -232.49, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21. Repligen Co. has a 1-year low of $102.97 and a 1-year high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. The business had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.28 EPS. As a group, research analysts forecast that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analysts Set New Price Targets

RGEN has been the subject of several research reports. Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price for the company in a research note on Tuesday, April 29th. Canaccord Genuity Group lowered their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. TD Cowen began coverage on shares of Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 target price on the stock. JPMorgan Chase & Co. reduced their target price on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Finally, Royal Bank of Canada lowered their price target on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $173.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.